What is the price of Acorda Therapeutics, Inc. (ACOR)

The price of Acorda Therapeutics, Inc. (ACOR) is $0.879

What is the market cap of Acorda Therapeutics, Inc. (ACOR)

The market cap of Acorda Therapeutics, Inc. (ACOR) is $582.38K

Acorda Therapeutics, Inc. (ACOR) Revenue

Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.

Year	Revenue	Change
Not enough data for the provided dates.

Year

Revenue

Change

Not enough data for the provided dates.

Company	Revenue	Revenue Difference	Country
MERCK Kommanditgesellschaft auf Aktien MER.SW	-	-	DE
Merck KGaA MRK.DE	-	-	DE
Takeda Pharmaceutical Company Limited 4502.T	-	-	JP
Galderma Group AG GALD.SW	-	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	$6.61B	-	IN

Company

Revenue

Revenue Difference

Country